Onradivir

昂拉地韦

Report date: 2025/06/12 16:52:32
NMEFirst In Class

Base Information

Drug NameOnradivir
Drug Alias Name安睿威ZSP-1273ZSP1273ZSYM-005
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPolymerase basic protein 2 inhibitors
TargetsPolymerase basic protein 2
Therapy Area/IndicationsInfluenza A virus infectionsAcute Kidney InjuryHepatic Insufficiency +[4] 
Global Approved IndicationsInfluenza A virus infections
Approved Indications in ChinaInfluenza A virus infections
Original Approved Country/TerritoryMainland China
Original Approved Date2025/05/20
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGuangdong Raynovent Biotech Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesGuangdong Raynovent Biotech Co Ltd
Inactive CompaniesGuangdong Zhongsheng Pharmaceutical Co LtdGuangdong Huanan Pharmaceutical Group Co Ltd
Active IndicationsInfluenza A virus infectionsAcute Kidney InjuryHepatic Insufficiency
Inactive IndicationsInfluenza, Human

Other Information

ATC CodeN/A
Related LinksN/A